Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07850306.7Aexternal-prioritypatent/EP2102224B2/en
Application filed by Mitsubishi Tanabe Pharma CorporationfiledCriticalMitsubishi Tanabe Pharma Corporation
Publication of CY1114969T1publicationCriticalpatent/CY1114969T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Μια νέα κρυσταλλική μορφή ημιένυδρου 1-(β-D-γλυκοπυρανοζυλο)-4-μεθυλο-3-[5- (4-φθοροφαινυλο)-2-θειενυλομεθυλο]βενζολίου, η οποία έχει ευνοϊκά χαρακτηριστικά, χαρακτηρίζεται από το χαρακτηριστικό διάγραμμα περίθλασης ακτίνων Χ από σκόνη και/ή από το φάσμα υπερύθρου αυτής.A novel crystalline form of 1- (β-D-glycopyranosyl) -4-methyl-3- [5- (4-fluorophenyl) -2-thienylmethyl] benzene hemihydrate, which has favorable characteristics, is characterized by the X-ray diffraction pattern. from dust and / or its infrared spectrum.
CY20141100129T2006-12-042014-02-19
Crystalline form of 1- (β-D-glycopyranosyl) -4-methyl- 3- [5- (4-fluorophenyl) -2- thienylmethyl] benzene
CY1114969T1
(en)
method for making simvastatin, composition of matter, method of making huvastatin, method of making simvastatin, and method of making a composition of matter of simvastatin or huvastatin